Mar Tintoré

Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS 3:10
Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS
Mar Tintoré • 4 Nov 2022
The ECTRIMS 2022 Event for People with MS 1:53
The ECTRIMS 2022 Event for People with MS
Mar Tintoré • 4 Nov 2022
Biomarkers of disease activity and treatment response in MS 3:10
Biomarkers of disease activity and treatment response in MS
Mar Tintoré • 4 Nov 2022
Addressing PIRA and PROMs in clinical practice 1:39
Addressing PIRA and PROMs in clinical practice
Mar Tintoré • 4 Nov 2022
Key updates and research focuses at ECTRIMS 2022 7:37
Key updates and research focuses at ECTRIMS 2022
Mar Tintoré • 4 Nov 2022
Limitations of the current multiple sclerosis classification 3:14
Limitations of the current multiple sclerosis classification
Mar Tintoré • 4 Oct 2021
Relapse-independent progression in multiple sclerosis 1:50
Relapse-independent progression in multiple sclerosis
Mar Tintoré • 4 Oct 2021
Incorporating new measures to detect silent progression in multiple sclerosis 2:11
Incorporating new measures to detect silent progression in multiple sclerosis
Mar Tintoré • 4 Oct 2021
Key areas of research in multiple sclerosis 4:03
Key areas of research in multiple sclerosis
Mar Tintoré • 4 Oct 2021
Barcelona_BRS to predict long-term prognosis in MS patients 2:39
Barcelona_BRS to predict long-term prognosis in MS patients
Mar Tintoré • 4 Oct 2021
Future challenges for MS research: progressive disease 2:12
Future challenges for MS research: progressive disease
Mar Tintoré • 7 Jun 2021
S1P receptor modulators in the treatment of MS 5:31
S1P receptor modulators in the treatment of MS
Mar Tintoré • 7 Jun 2021
How to individualize MS treatment decisions? 12:15
How to individualize MS treatment decisions?
Mar Tintoré • 7 Jun 2021
The content of VJNeurology is intended for healthcare professionals